In type 2 diabetes, exposure of monocytic cells to inflammatory stimuli can lead to aberrant cytoskeletal remodelling and contribute to the development of diabetic microangiopathy. Previous studies within our research group have demonstrated that Rosiglitazone significantly reduces formyl-methionyl-leucyl-proline (f-MLP)-induced actin polymerization in monocytes by increasing cytosolic calcium ion concentrations ([Ca 2þ ] i ) in both resting and f-MLP-stimulated cells. As the timescale of this effect resembled inhibition of SERCA2b, the 'housekeeping' Ca 2þ pump enzyme that sequesters Ca 2þ into the ER compensatory to non-specific leakage into the cytoplasm, the present study sought to test the hypothesis that Rosiglitazone-induced increases in [Ca 2þ ] i are brought about by inhibition of SERCA2b, and also investigated how such changes are transduced into cytoskeletal remodelling.
In type 2 diabetes, exposure of monocytic cells to inflammatory stimuli can lead to aberrant cytoskeletal remodelling and contribute to the development of diabetic microangiopathy. Previous studies within our research group have demonstrated that Rosiglitazone significantly reduces formyl-methionyl-leucyl-proline (f-MLP)-induced actin polymerization in monocytes by increasing cytosolic calcium ion concentrations ([Ca 2þ ] i ) in both resting and f-MLP-stimulated cells. As the timescale of this effect resembled inhibition of SERCA2b, the 'housekeeping' Ca 2þ pump enzyme that sequesters Ca 2þ into the ER compensatory to non-specific leakage into the cytoplasm, the present study sought to test the hypothesis that Rosiglitazone-induced increases in [Ca 2þ ] i are brought about by inhibition of SERCA2b, and also investigated how such changes are transduced into cytoskeletal remodelling.
Coupled-enzyme Ca 2þ -ATPase assays revealed a SERCA2b activity of 49 + 5 nmol/mg/min in monocytic microsomes but pre-incubation with Rosiglitazone (20 mM; 30 min) induced statistically significant inhibition of this activity (P , 0.05). Permeabilization of cultured monocytes in external solutions containing differing [Ca 2þ ] free was used to manipulate [Ca 2þ ] i , and F-actin content measured using flow cytometric analysis of FITC-phalloidin fluorescence. At [Ca 2þ ] i .100 nM, a significant decrease in cells' F-actin content was observed (P , 0.05). In conditions of minimal [Ca 2þ ] i , f-MLP exerted a polymerizing effect on the actin cytoskeleton; however, as [Ca 2þ ] i was increased to .100 nM, this polymerizing effect was significantly reduced.
Finally, as a literature search identified the Ca 2þ -dependent actin-modulating protein gelsolin as a candidate for transducing changes in [Ca
Introduction
Type 2 diabetes mellitus (T2D) is a common condition caused by the lack or diminished effectiveness of insulin, and is characterized by hyperglycaemia and other disruptions in metabolism. The condition is associated with a host of long-term complications that generally fall into two distinct categories, namely macrovascular and microvascular, which together constitute the major causes of morbidity and mortality amongst the diabetic population. 1 In T2D, constant exposure of monocytic cells to inflammatory stimuli, such as the ligation of advanced glycation end products (AGEs) to their receptors on cell surface membranes, results in hyperactivation: a state characterized by increased polymerization of globular actin (G-actin) to the filamentous form (F-actin), which is accompanied by a concurrent reduction in cell deformability. 2 Such aberrant monocytic development of diabetic microangiopathy and thus confer an increased risk for the progression of the microvascular complications of the disease, which include retinopathy, nephropathy, and neuropathy. 3 Rosiglitazone is an anti-hyperglycaemic agent belonging to a group of compounds known as the thiazolidinediones (TZDs) that, owing to their role as ligands for the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR-g), are used extensively to improve insulin sensitivity in individuals with T2D. 4 Recently, our research group has demonstrated that in vitro treatment of human monocytic cells with Rosiglitazone significantly reduces the actin polymerization seen in response to the pro-inflammatory peptide formyl-methionyl-leucyl-proline (f-MLP).
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A similar decrease in f-MLP-induced actin polymerization was also observed in peripheral monocytes isolated from the blood of diabetic patients following a 3-month course of Rosiglitazone therapy (compared with peripheral monocytes from patients prescribed an alternative anti-diabetic drug, Gliclazide). 6 Thus, these data suggest that in addition to its insulin-sensitizing effects, Rosiglitazone may possess the capacity to modulate the rigidity of the actin cytoskeleton of monocytes, and thus possibly confer a level of protection against the development of diabetic microangiopathy. Since actin cytoskeletal remodelling is considered to be a Ca 2þ -dependent process, 7, 8 it is interesting to note that 
Maintenance of cells in culture
Monocytic MM6 cells were cultured (378C; 5% CO 2 ) in RPMI 1640 medium supplemented with 10% (v/v) foetal calf serum, 1 mM non-essential amino acids, 2 mM L-glutamine and 1 mM sodium pyruvate and were subcultured when a density of 0.8 -1.00 Â 10 6 cells/ml was attained. Cells of .90% viability (as determined by Trypan blue exclusion) and passage number ,30 were used in all instances, prior to harvesting of MM6 cells for further experiments.
Subcellular fractionation
MM6 microsomes were prepared by the method of Maruyama and MacLennan. 18 Briefly, MM6 cells were homogenized, and whole-cell homogenates subjected to differential centrifugation so as to obtain different subcellular fractions, including microsomes. Previous analyses have For the measurement of [Ca 2þ ] free , 75 ml aliquots of permeabilization buffer (10 mM Hepes, 140 mM KCl, 1 mM MgCl 2 , 10 mM glucose, 1 mM ATP, pH 7.0) were transferred to fluorescence spectrophotometric cuvettes. 3 mM Fluo-3-AM was added to each cuvette, and fluorescence measured using a Perkin-Elmer Fluorescence Spectrophotometer with Perkin-Elmer Data Manager Software. Samples were excited at 506 nm and an emission scan performed between 510-600 nm; data were corrected for autofluorescence using measurements obtained from a solution of permeabilization buffer that had not been loaded with dye. To one cuvette, 10 ml of 100 mM CaCl 2 (final concentration $13 mM) was added to obtain a solution with maximal (i.e. saturating) Ca 2þ ; to another 10 ml of 100 mM EGTA was added to obtain a solution with minimal Ca 2þ ; while to the remaining cuvettes, 0. ). These observed data were then compared with predicted [Ca 2þ ] free data, as calculated using CACONC.
Flow cytometry
The F-actin content of MM6 cells was determined using FITC-phalloidin, a fluorescently labelled derivative of the Amanita phalloides metabolite phalloidin, whose fluorescence has been reported to correlate with cellular F-actin content. 23 Briefly, 10 7 cells were sedimented by centrifugation at 250g for 5 min, resuspended in 5 ml of ice-cold permeabilization buffer and pelleted (250g; 5 min). The resultant cell pellet was resuspended in ice-cold permeabilization buffer, and 300 ml aliquots of this suspension transferred to 0.4 cm 3 electroporation cuvettes and subjected to an electrical pulse (200 V; 975 mF; t 1 2 , ,30 ms) using a Bio-Rad Gene Pulser II (Bio-Rad Laboratories). Following electroporation, 0.9 ml of 100 mM EGTA and aliquots of 100 mM CaCl 2, ( predicted by CACONC to result in [Ca 2þ ] free values of 2.88 mM, 0.75 mM, 0.25 mM and 83 nM)
were added to 75 ml aliquots of the cell suspension, and cells allowed to equilibrate for 1 min at room temperature, before addition of FITC-phalloidin (1.65 mM) to each aliquot of cells, which were then incubated for 10 min at room temperature. Cells were then either fixed immediately by the addition of 10 ml of 37% phosphate-buffered formalin, or were fixed subsequent to incubation with 10 ml of 100 nM f-MLP for 5 min at 378C. After fixation, cells were washed (Â2) and resuspended in 0.5 ml of PBS, prior to analysis using a Beckman-Coulter Cytomecs-FC500-MPL FACS with FlowCytomix Pro1.0 software. The samples were excited by an argon laser at 488 nm and emission measured at 530 nm. Gating of cells was performed to exclude cellular debris, and the fluorescence intensity of each sample recorded as the gated x-mean. Autofluorescence was corrected for by analysis of fixed and unfixed electroporated cells in the absence of dye or f-MLP.
Western blot analysis
To confirm the expression of intracellular gelsolin in MM6 cells, total cell protein lysates were subjected to western blot analyses. 5 Â 10 6 cells were sedimented by centrifugation at 300g for 10 min, washed (Â3) in PBS, resuspended in 118 ml of lysis buffer (10 mM Tris -HCl pH 7.2, 100 mM NaCl, 2 mM EDTA, 0.5% w/v sodium deoxycholate, 1% v/v NonidetP40) and 12 ml of protease cocktail inhibitor, and maintained on ice for 30 min, during which time they were vortexed at three separate intervals. Samples were sonicated on ice for 10 s and centrifuged at 8000g for 5 min at 
Statistical analysis
The data presented in Fig. 2 were analysed by analysis of variance (ANOVA), while the data presented in Fig. 3 , the Ca 2þ -ATPase data and the data from the experiment designed to investigate the effect of f-MLP on the F-actin content of cells were analysed by two-sample t-tests. Significance levels were set at P , 0.05. .................................................................................................................................................................................................................................. above resting levels (.100 nM) resulted in a substantial decrease in the F-actin content of cells (Fig. 2) . ................................................................................................................................................................................................................................. investigated was shown to be associated with non-significant increases in the F-actin content of cells above basal ( Fig. 3 ; P . 0.05 in all cases; n ¼ 4; values for basal F-actin levels were derived from preliminary experiments performed at each [Ca 2þ ] i value in the absence of f-MLP). In all instances, this increase was observed to be less than that apparent in the earlier 'positive control' experiment ($170%, shown as the first data point in Fig. 3 ). Thus, although it is somewhat difficult to establish a clear trend, it would appear that as the level of [Ca 2þ ] i is increased above resting levels, the polymerizing effect of f-MLP diminishes so that it no longer attains statistical significance. It is therefore possible to state that, in our experimental system, the depolymerizing effect of Ca 2þ may override the polymerizing action of f-MLP.
Results

Gelsolin expression in MM6 cells
In western blot experiments (Fig. 4) likely that the capacity of Rosiglitazone to inhibit the activity of SERCA2b represents a non-genomic effect of the drug, since inhibitory activity was evident following relatively short periods of incubation (30 min) and was observed in microsomal fractions that lack nuclear proteins such as PPAR-g. 18 When considering the relevance of these data in a clinical context, it is important to be aware that the concentration of Rosiglitazone selected in the current study is not strictly applicable to the in vivo state where the peak plasma concentration of the drug is estimated to be $0.8 mM. 29 (Fig. 2) or the presence (Fig. 3) of activating cell stimuli. Since the expression of gelsolin-as seen here in MM6 cells (Fig. 4) -has been reported in a wide variety of cell types, 13 and as the actin depolymerizing activity of gelsolin is Ca 2þ -dependent, 30 above resting levels, the polymerizing effect of f-MLP diminishes so that it no longer attains statistical significance (Fig. 3) . f-MLP was utilized in this investigation as a surface receptor agonist with which to mimic the inflammatory stimuli, such as AGEs, to which monocytic cells are exposed in T2D. Therefore, our data suggest that Rosiglitazone, via its ability to modulate monocytic Ca 2þ signalling processes, may serve to counter the promotion of excessive actin polymerization in monocytes following exposure to inflammatory stimuli, as seen in the diabetic milieu. 32 Thus, our data suggest that treatment of monocytic cells with pharmacologically relevant concentrations of Rosiglitazone leads to inhibition of SERCA2b resulting in elevations in [Ca 2þ ] i . Such perturbations in [Ca 2þ ] i subsequently facilitate actin cytoskeletal depolymerization, possibly via activation of the Ca 2þ -dependent actinmodulating protein gelsolin, which ultimately results in increased deformability of monocytes, and as such may confer a level of protection against the development of diabetic microangiopathy. The observation that the depolymerizing effect of Ca 2þ appears to override the polymerizing action of activating cell stimuli provides a sound rationale for the potentially beneficial effects of Rosiglitazone on modulating the actin cytoskeleton of hyperactivated monocytes. However, further investigations, perhaps involving in vitro studies using AGEs as inflammatory stimuli of direct relevance to T2D, and-in the long-term-patient studies would be recommended to test the validity of these initial hypotheses.
Finally, given the current controversy linking treatment with Rosiglitazone to an increased risk of myocardial infarction and of death from cardiovascular causes, 15, 16 it is worth considering the relevance of the data obtained in the present study to these recent clinical concerns. In cardiomyocytes, contraction is triggered by transient increases in [Ca 2þ ] i , while relaxation is mediated by the rapid sequestration of cytosolic Ca 2þ predominantly through SERCA2a (the alternatively-spliced isoform of SERCA2b 24 ), the activity of which is modulated by an accessory polypeptide, phospholamban. 33 Studies involving genetically engineered mouse models have demonstrated that the hearts of SERCA2a heterozygous mutants exhibited decreased cardiac function, while models overexpressing a mutant form of phospholamban displayed depressed contractile parameters, which ultimately led to heart failure and death. 34 Such data highlight the importance of Ca 2þ -regulatory proteins to the correct functioning of the heart and suggest that while the capacity for Rosiglitazone to inhibit SERCA2 may be clinically beneficial in the context of hyperactivated diabetic monocytes, it has the potential to be deleterious in the context of the cardiomyocyte. It must be stressed, however, that it remains to be seen whether the mechanisms via which Rosiglitazone disrupts Ca 2þ homeostasis in monocytes also operate in other cell types, and thus further investigation is recommended in order for a clearer picture to emerge.
